Introduction

Agomelatine is a potent MT1 and MT2 melatonin receptor agonist and a 5-HT2C serotonin receptor antagonist. The purpose of this study was to show the convulsion-reducing effect of agomelatine, in both clinical and electrophysiological terms, in a pentylenetetrazole (PTZ)-induced experimental epilepsy model in rats.

Methods

The anticonvulsant activity of agomelatine (25 and 50 mg/kg) was evaluated in rat models of PTZ (35 and 70 mg/kg) and compared with the control groups.

Results

Agomelatine administration at doses of 25 and 50 mg/kg resulted in a statistically significant decrease in convulsion scores and time to onset of myoclonic jerks compared to the control groups. In addition, comparison of the two doses employed showed that high-dose agomelatine (50 mg/kg) was significantly more effective than the lower dose. In addition to previous studies, we investigated the anticonvulsant effect of agomelatine using electroencephalogram (EEG). Administration of agomelatine at doses of 25 and 50 mg/kg in PTZ-induced seizures caused a significant decrease in the percentage of peak at EEG.

Discussion

Our results suggest that agomelatine has anticonvulsant activity shown in PTZ-induced seizure model. The results also give some evidences that agomelatine can use on epileptic seizures, but more studies are needed.

中文翻译：

---

阿戈美拉汀对戊四唑致惊厥的减轻作用

介绍

阿戈美拉汀是一种有效的 MT1 和 MT2 褪黑激素受体激动剂和 5-HT2C 血清素受体拮抗剂。本研究的目的是在戊四唑 (PTZ) 诱导的大鼠实验性癫痫模型中，从临床和电生理学角度显示阿戈美拉汀的惊厥减少作用。

方法

在 PTZ（35 和 70 毫克/公斤）大鼠模型中评估阿戈美拉汀（25 和 50 毫克/公斤）的抗惊厥活性，并与对照组进行比较。

结果

与对照组相比，阿戈美拉汀以 25 和 50 mg/kg 的剂量给药导致惊厥评分和肌阵挛发作时间显着降低。此外，所采用的两种剂量的比较表明，高剂量阿戈美拉汀 (50 mg/kg) 比低剂量明显更有效。除了先前的研究外，我们还使用脑电图 (EEG) 研究了阿戈美拉汀的抗惊厥作用。在 PTZ 诱发的癫痫发作中以 25 和 50 mg/kg 的剂量施用阿戈美拉汀导致 EEG 峰值百分比显着降低。

讨论

我们的结果表明，阿戈美拉汀在 PTZ 诱导的癫痫模型中具有抗惊厥活性。结果还提供了一些证据表明阿戈美拉汀可以用于癫痫发作，但还需要更多的研究。